Literature DB >> 10348778

Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis.

K Wolf1, R Malinverni.   

Abstract

Azithromycin, doxycycline, and rifampin, alone or in combination, were tested in vitro against Chlamydia pneumoniae AR-39. The combination of azithromycin plus rifampin showed the strongest activity and produced higher rates of eradication of C. pneumoniae from lung tissues than azithromycin alone in experimental mouse pneumonitis.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10348778      PMCID： PMC89304          DOI： 10.1128/AAC.43.6.1491

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

2.  In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin.

Authors:  J D Treharne; P J Yearsley; R C Ballard
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  In vitro drug susceptibility of Chlamydia sp. strain TWAR.

Authors:  C C Kuo; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 4.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Infective endocarditis complicating psittacosis: response to rifampicin.

Authors:  A G Jariwalla; B H Davies; J White
Journal:  Br Med J       Date:  1980-01-19

6.  Treatment of nongonococcal urethritis with rifampicin as a means of defining the role of Ureaplasma urealyticum.

Authors:  E D Coufalik; D Taylor-Robinson; G W Csonka
Journal:  Br J Vener Dis       Date:  1979-02

7.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Detection of Chlamydia pneumoniae by polymerase chain reaction.

Authors:  L A Campbell; M Perez Melgosa; D J Hamilton; C C Kuo; J T Grayston
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

9.  In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.

Authors:  R B Jones; G L Ridgway; S Boulding; K L Hunley
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis.

Authors:  W R Bowie; C K Lee; E R Alexander
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226
View more
  9 in total

1.  Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Ana María Ríos; Mónica Fonseca-Aten; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana María Gómez; George H McCracken; Octavio Ramilo; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles.

Authors:  Udaya S Toti; Bharath R Guru; Mirabela Hali; Christopher M McPharlin; Susan M Wykes; Jayanth Panyam; Judith A Whittum-Hudson
Journal:  Biomaterials       Date:  2011-06-08       Impact factor: 12.479

3.  Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice.

Authors:  X X Bin; K Wolf; T Schaffner; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

4.  Growth cycle-dependent pharmacodynamics of antichlamydial drugs.

Authors:  Katrin Siewert; Jan Rupp; Matthias Klinger; Werner Solbach; Jens Gieffers
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  New perspectives of infections in cardiovascular disease.

Authors:  Ignatius W Fong
Journal:  Curr Cardiol Rev       Date:  2009-05

Review 6.  Causality of Chlamydiae in Arthritis and Spondyloarthritis: a Plea for Increased Translational Research.

Authors:  Henning Zeidler; Alan P Hudson
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

7.  Atherosclerosis Induced by Chlamydophila pneumoniae: A Controversial Theory.

Authors:  Hamidreza Honarmand
Journal:  Interdiscip Perspect Infect Dis       Date:  2013-07-17

8.  Gene Deletion by Fluorescence-Reported Allelic Exchange Mutagenesis in Chlamydia trachomatis.

Authors:  Konrad E Mueller; Katerina Wolf; Kenneth A Fields
Journal:  MBio       Date:  2016-01-19       Impact factor: 7.867

9.  Enrofloxacin and macrolides alone or in combination with rifampicin as antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection.

Authors:  Annette Prohl; Markus Lohr; Carola Ostermann; Elisabeth Liebler-Tenorio; Angela Berndt; Wieland Schroedl; Michael Rothe; Evelyn Schubert; Konrad Sachse; Petra Reinhold
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.